DeepMed Research

ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris

Phase 4

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Dapsone
Drug: Tazarotene

First Posted Date: 2009-02-03

Last Posted Date: 2011-10-31

Lead Sponsor: Allergan

Target Recruit Count: 171

Registration Number: NCT00834210

Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris

Phase 4

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Dapsone; Tretinoin
Drug: Tretinoin

First Posted Date: 2009-02-03

Last Posted Date: 2011-10-31

Lead Sponsor: Allergan

Target Recruit Count: 163

Registration Number: NCT00835198

A Natural History Study of Patients With Dry Eye

Completed

Conditions: Dry Eye

Interventions: Other: Artificial Tears

First Posted Date: 2009-02-02

Last Posted Date: 2017-07-25

Lead Sponsor: Allergan

Target Recruit Count: 284

Registration Number: NCT00833235

Locations: 🇺🇸
Jones Eye Institute, Little Rock, Arkansas, United States
🇺🇸
North Valley Eye Medical Group, Inc., Mission Hills, California, United States
🇺🇸
Eye Center of Northern Colorado, Fort Collins, Colorado, United States

and more 14 locations

Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris

Phase 4

Terminated

Conditions: Acne Vulgaris

Interventions: Drug: Tazarotene Cream 0.1%
Drug: Adapalene

First Posted Date: 2009-01-26

Last Posted Date: 2012-09-12

Lead Sponsor: Allergan

Target Recruit Count: 165

Registration Number: NCT00829049

Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

Completed

Conditions: Dry Eye Disease

Interventions: Drug: Cyclosporine Ophthalmic Emulsion 0.05%

First Posted Date: 2009-01-22

Last Posted Date: 2019-04-25

Lead Sponsor: Allergan

Target Recruit Count: 35

Registration Number: NCT00827255

Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Phase 4

Completed

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
Drug: dorzolamide hcl 2%/timolol maleate 0.5% fixed combination
Drug: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination
Drug: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy

First Posted Date: 2009-01-14

Last Posted Date: 2009-01-14

Lead Sponsor: Allergan

Target Recruit Count: 140

Registration Number: NCT00822055

Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow

Phase 4

Completed

Conditions: Glaucoma

Interventions: Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution
Drug: fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution

First Posted Date: 2008-12-19

Last Posted Date: 2019-04-24

Lead Sponsor: Allergan

Target Recruit Count: 15

Registration Number: NCT00811850

An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects

Phase 4

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution
Drug: latanoprost 0.005%

First Posted Date: 2008-12-19

Last Posted Date: 2011-09-21

Lead Sponsor: Allergan

Target Recruit Count: 148

Registration Number: NCT00811564

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Phase 1

Completed

Conditions: Ocular Hypertension
Glaucoma

Interventions: Drug: AGN-210669 ophthalmic solution, 0.025%
Drug: AGN-210669 ophthalmic solution, 0.05%
Drug: bimatoprost ophthalmic solution 0.03%
Drug: AGN-210669 ophthalmic solution, 0.075%
Drug: AGN-210669 vehicle ophthalmic solution

First Posted Date: 2008-12-17

Last Posted Date: 2013-10-18

Lead Sponsor: Allergan

Target Recruit Count: 172

Registration Number: NCT00809848

Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema

Phase 2

Completed

Conditions: Vitrectomy
Diabetic Macular Edema

Interventions: Drug: Dexamethasone

First Posted Date: 2008-11-27

Last Posted Date: 2019-04-23

Lead Sponsor: Allergan

Target Recruit Count: 56

Registration Number: NCT00799227

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy